Related Experiment Video
Updated: May 22, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Yasada bhasma : an effective hypoglycaemic drug
1Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi- 835 215, India.
Ancient Science of Life
|May 5, 2012
Summary
Yasada bhasma, a traditional Ayurvedic preparation, demonstrated significant hypoglycemic effects in experimental animal studies. This research highlights its potential as an effective treatment for managing blood sugar levels.
Area of Science:
- Ayurvedic Medicine
- Pharmacology
- Biomedical Science
Background:
- Traditional Indian medicine utilizes various bhasmas for therapeutic purposes.
- Yasada bhasma is an Ayurvedic formulation containing zinc compounds.
- Understanding the pharmacological actions of traditional remedies is crucial for modern healthcare.
Purpose of the Study:
- To conduct a comprehensive bioevaluation of yasada bhasma.
- To assess the hypoglycemic potential of yasada bhasma in vivo.
- To provide scientific validation for the traditional use of yasada bhasma in managing blood glucose.
Main Methods:
- Bioevaluation studies were performed on experimental animal models.
- Standardized protocols for drug administration and monitoring were employed.
- Blood glucose levels were assessed to determine the hypoglycemic activity.
Main Results:
- The bioevaluation confirmed yasada bhasma's efficacy.
- Yasada bhasma was found to be a highly effective hypoglycemic agent.
- Significant reductions in blood glucose levels were observed in treated animals.
Conclusions:
- Yasada bhasma exhibits potent hypoglycemic properties.
- The findings support the use of yasada bhasma as a therapeutic agent for hyperglycemia.
- Further research into the mechanisms of action is warranted.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...